Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%0700.HK-6.19%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.76%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.70%0857.HK-1.46%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.09%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.69%AUDUSD-1.56%EURAUD+1.01%AUDCHF-0.99%AUDCAD-0.99%GBPAUD+0.93%AUDNZD-0.88%NZDJPY-0.82%GBPJPY-0.76%CADJPY-0.71%EURJPY-0.71%CHFJPY-0.70%NZDUSD-0.67%AUDSGD-0.62%GBPUSD-0.61%USDCHF+0.60%USDCAD+0.58%AUDDKK-0.56%EURUSD-0.56%USDZAR+0.44%GBPTRY+0.41%USDMXN+0.41%AUDNOK-0.37%USDTHB+0.35%NZDMXN+0.32%GBPHKD+0.32%EURZAR+0.31%USDNOK+0.30%GBPMXN-0.28%GBPZAR+0.28%CHFNOK+0.26%NOKJPY-0.24%USDTRY+0.21%USDSEK+0.19%EURNOK+0.19%USDPLN+0.17%USDILS+0.16%USDJPY-0.15%EURCNH-0.15%CHFSEK+0.14%EURHKD-0.13%USDCNH-0.12%NZDCAD-0.12%USDDKK+0.12%EURNZD+0.11%NZDCHF-0.11%GBPSGD-0.09%PLNJPY-0.09%EURSEK+0.08%EURGBP+0.06%GBPNZD+0.06%USDSGD+0.06%EURSGD-0.06%GBPCAD-0.05%EURPLN+0.05%EURCZK+0.04%EURCHF+0.04%USDCOP-0.04%SGDJPY+0.02%GBPCHF-0.02%EURCAD+0.02%USDHKD-0.01%CADCHF+0.01%NZDSGD-0.01%CHFSGD0.00%EURDKK0.00%XPTUSD-1.14%XAGUSD-0.95%GAGUSD-0.95%XAUUSD-0.64%GAUUSD-0.64%HG1-0.53%W1-0.47%XNGUSD-0.44%C1-0.29%UKOIL+0.28%S1-0.15%USOIL+0.05%BTCUSD-3.70%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.67%ZECUSDT-7.39%XMRUSDT-2.17%DOGEUSD+55.95%LINKUSD-3.57%XLMUSD-3.94%BCHUSDT-3.64%LTCUSD+47.50%UNIUSD-3.19%SUIUSD-3.36%TONUSD+59.18%HBARUSDT-5.48%TAOUSDT-3.60%AAVEUSD-3.76%ONDOUSDT-5.67%ICPUSDT-2.09%DOTUSDT-4.17%WLDUSDT-3.94%ARBUSDT-5.98%ATOMUSDT-2.61%INJUSDT-8.15%STXUSDT-3.46%PYTHUSDT-1.58%TIAUSDT-3.65%FETUSDT-4.91%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.62%OPUSDT-3.90%IOTAUSDT-2.72%POLUSDT-2.17%WIFUSDT-2.98%AXSUSDT-3.20%EOSUSDT-4.53%IMXUSDT-3.86%FARTCOINUSDT-7.06%GALAUSDT-2.38%DYDXUSDT-3.30%ORDIUSDT-2.78%NOTUSDT-2.34%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%0700.HK-6.19%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.76%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.70%0857.HK-1.46%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.09%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.69%AUDUSD-1.56%EURAUD+1.01%AUDCHF-0.99%AUDCAD-0.99%GBPAUD+0.93%AUDNZD-0.88%NZDJPY-0.82%GBPJPY-0.76%CADJPY-0.71%EURJPY-0.71%CHFJPY-0.70%NZDUSD-0.67%AUDSGD-0.62%GBPUSD-0.61%USDCHF+0.60%USDCAD+0.58%AUDDKK-0.56%EURUSD-0.56%USDZAR+0.44%GBPTRY+0.41%USDMXN+0.41%AUDNOK-0.37%USDTHB+0.35%NZDMXN+0.32%GBPHKD+0.32%EURZAR+0.31%USDNOK+0.30%GBPMXN-0.28%GBPZAR+0.28%CHFNOK+0.26%NOKJPY-0.24%USDTRY+0.21%USDSEK+0.19%EURNOK+0.19%USDPLN+0.17%USDILS+0.16%USDJPY-0.15%EURCNH-0.15%CHFSEK+0.14%EURHKD-0.13%USDCNH-0.12%NZDCAD-0.12%USDDKK+0.12%EURNZD+0.11%NZDCHF-0.11%GBPSGD-0.09%PLNJPY-0.09%EURSEK+0.08%EURGBP+0.06%GBPNZD+0.06%USDSGD+0.06%EURSGD-0.06%GBPCAD-0.05%EURPLN+0.05%EURCZK+0.04%EURCHF+0.04%USDCOP-0.04%SGDJPY+0.02%GBPCHF-0.02%EURCAD+0.02%USDHKD-0.01%CADCHF+0.01%NZDSGD-0.01%CHFSGD0.00%EURDKK0.00%XPTUSD-1.14%XAGUSD-0.95%GAGUSD-0.95%XAUUSD-0.64%GAUUSD-0.64%HG1-0.53%W1-0.47%XNGUSD-0.44%C1-0.29%UKOIL+0.28%S1-0.15%USOIL+0.05%BTCUSD-3.70%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.67%ZECUSDT-7.39%XMRUSDT-2.17%DOGEUSD+55.95%LINKUSD-3.57%XLMUSD-3.94%BCHUSDT-3.64%LTCUSD+47.50%UNIUSD-3.19%SUIUSD-3.36%TONUSD+59.18%HBARUSDT-5.48%TAOUSDT-3.60%AAVEUSD-3.76%ONDOUSDT-5.67%ICPUSDT-2.09%DOTUSDT-4.17%WLDUSDT-3.94%ARBUSDT-5.98%ATOMUSDT-2.61%INJUSDT-8.15%STXUSDT-3.46%PYTHUSDT-1.58%TIAUSDT-3.65%FETUSDT-4.91%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.62%OPUSDT-3.90%IOTAUSDT-2.72%POLUSDT-2.17%WIFUSDT-2.98%AXSUSDT-3.20%EOSUSDT-4.53%IMXUSDT-3.86%FARTCOINUSDT-7.06%GALAUSDT-2.38%DYDXUSDT-3.30%ORDIUSDT-2.78%NOTUSDT-2.34%RONINUSDT-2.92%
XB

Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ • Healthcare

$16.98
+$0.18 (+1.1%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$16.93
Day Range$16.72 - $17.28
Avg. Volume (3M)3.3M
Market Cap$3.1B
52 Week Range
$5.25$17.28

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$107.2M100%
Gross Profitminus cost of goods$94.7M88%
Operating Incomeminus R&D and overhead$16.9M16%
Net Incomeminus taxes and the rest$11.2M11%

In plain terms: out of every $100 in revenue, Xeris Biopharma Holdings, Inc. keeps $11 as net profit.

Fundamentals & Financials

Revenue (TTM)
$368.2M
Net Income (TTM)
-$6.4M
EPS (TTM)
-$0.04
ROA (TTM)
-1.53%
Current Ratio
2.15

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+465.0%Q2 2026$0.01
-1582.7%Q3 2026-$0.18
+89.5%Q4 2026$0.06

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +89.5%

Xeris Biopharma’s revenue beat expectations as sales climbed sharply year over year, based on preliminary results for the third fiscal quarter of 2026 reported on November 5, 2026. Revenue rose 44% to about $107.2 million (up from about $74.4 million a year ago) and topped consensus, with revenue of $107.2 million versus the $101.7 million estimate (+5.4%). Profitability was supported by high product-level margins, with gross margin at roughly 88% and operating margin near 16%, alongside operating income of about $16.9 million on gross profit of roughly $94.8 million. Cash generation also stood out, with operating cash flow of about $35.5 million, and the company repurchased about $0.8 million of stock during the period. For the next period, consensus calls for EPS of $0.03 on revenue of $111.0 million.

View full earnings history

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. develops and commercializes specialty therapies in biotechnology, centered on endocrinology, neurology, and gastroenterology, and generated $291.8 million of revenue in FY2025. The NASDAQ-listed company, traded as XERS, builds its portfolio around proprietary formulation technologies and a focused set of marketed products.

Name
Xeris Biopharma Holdings, Inc.
CEO
John Shannon
Industry
Healthcare
Year Founded
2005
Employees
435

Today's Snapshot

AI-generated

XERS closed 1.1% above yesterday's close, outperforming a weaker sector. Trading was lighter than usual, with volume about half of its usual level. Xeris Biopharma raised its revenue forecast.

Trading Volume

Below 10d avg (4.7M)

2.7M

vs S&P 500 Today

Outperforming Market

+1.39%

Updated: November 18, 2026 at 21:10 UTC

Technical Indicators

6 Buy0 Neutral2 Sell
XERS displays a powerful upward trend backed by a high ADX and very strong volume accumulation, and the price sits well above virtually all moving averages including the long-term ones. Momentum and MACD are positive, but oscillators are deeply overbought, signaling stretched near-term conditions while ATR remains moderate. The contrast between strong trend/volume readings and overbought oscillators suggests strong underlying demand with limited short-term breath. Technical takeaway: Strong Buy.
All signals
  • EMA (5 indicators)$8.73 - $15.66
    Buy
  • RSI (14)86.29
    Sell
  • Stochastic %K (14, 3, 3)96.44
    Sell
  • MACD Level (12, 26)1.87
    Buy
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.